Enfoque clínico del paciente con síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. Parte I: Epidemiología, Diagnóstico y Factores Pronósticos

Simple item page
dc.coverageDOI: 10.4067/s0034-98872025000400294
dc.creatorLobos, Nelson
dc.creatorValenzuela, Fernando
dc.creatorMolgó, Monserrat
dc.creatorLópez, Valeska
dc.creatorPalisson, Francis
dc.date2025
dc.date.accessioned2025-11-18T19:52:56Z
dc.date.available2025-11-18T19:52:56Z
dc.description<p>Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe cutaneous manifestations of adverse drug reactions. This first review aims to provide an update on the epidemiological, pathophysiological, clinical manifestations, diagnostic, and prognostic aspects of these conditions. Aim: To establish an updated clinical approach to SJS/TEN based on current evidence. Methods: A search was conducted in indexed databases (PubMed, SciElo, LILACS), selecting 68 articles and 2 clinical guidelines from the Ministry of Health of Chile (MINSAL), from March to September 2024. Results: SJS/TEN affects genetically susceptible individuals with inappropriate immune responses triggered by drugs or non-pharmacological factors, leading to keratinocyte apoptosis and high mortality. Three hypotheses for T-cell activation are proposed: hapten/prohapten, p-i interaction, and altered peptide model. Key mediators include FasL, perforins, granzymes, and granulysin. Genetic factors, such as HLA alleles and CYP450 variants, influence susceptibility. Diagnosis relies on clinical and histopathological evaluation. Skin biopsy is crucial for confirmation, though treatment should not be delayed if there is a high suspicion. Tools such as causality algorithms and developing biomarcadores may aid in early identification of SJS/TEN, though further research is needed. Conclusions: Diagnosing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is challenging due to their variable clinical presentations and similarities with differential diagnoses. Biopsy is essential, but histopathological findings do not always distinguish between forms of SJS and TEN. Causality assessment tools and advancements in biomarkers show potential, but further validation is needed. This initial review allows for understanding the rationale behind the recommendations outlined in the second part of the review.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/47552158-8c77-4499-87e7-3ca0f9931e3c
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/57982
dc.languagespa
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.153 (2025) nr.4 p.294-303
dc.subjectAdverse Drug Reaction
dc.subjectApoptosis
dc.subjectDiagnosis
dc.subjectPrognosis
dc.subjectStevens-Johnson Syndrome
dc.subjectToxic Epidermal Necrolysis
dc.titleEnfoque clínico del paciente con síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. Parte I: Epidemiología, Diagnóstico y Factores Pronósticosspa
dc.titleClinical Approach to the Patient With Stevens-Johnson Syndrome And Toxic Epidermal Necrolysis. Part I: Epidemiology, Diagnosis, and Prognostic Factorseng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE